Besides these, huge prices have been paid by Sanofi for licensing novel treatment approaches european-biotechnology.com/up-to-date/latest-news/news/sanofi-takes-over-bioverativ-in-us118bn-deal.html in the competitive market currently dominated by Shire (FEIBA) and Novo Nordisk (NovoSeven) …
28
Mar